Cargando…
Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells
Non-small cell lung cancer (NSCLC), comprising 85% of lung cancer cases, has been associated with resistance to chemo/radiotherapy. The hypoxic tumor micro-environment, where insufficient vasculature results in poor drug penetrance and sub-optimal chemotherapy in the tumor interiors contributes heav...
Autores principales: | Pradhan, Shrikant, Mahajan, Divyank, Kaur, Prabhjot, Pandey, Namita, Sharma, Chandresh, Srivastava, Tapasya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342127/ https://www.ncbi.nlm.nih.gov/pubmed/27708247 http://dx.doi.org/10.18632/oncotarget.12378 |
Ejemplares similares
-
The in vitro development of cloned sheep embryos treated with Scriptaid and Trichostatin (A)
por: Al-Ghadi, Muath Q, et al.
Publicado: (2020) -
Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
por: Brown, J. M.
Publicado: (1998) -
Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma
por: Liu, Linlin, et al.
Publicado: (2018) -
Histone Deacetylase Inhibitor Scriptaid Alleviated Neurological Dysfunction after Experimental Intracerebral Hemorrhage in Mice
por: Yang, Heng, et al.
Publicado: (2018) -
SNP rs9387478 at ROS1-DCBLD1 Locus is Significantly Associated with Lung Cancer Risk and Poor Survival in Indian Population
por: Chongtham, Jonita, et al.
Publicado: (2022)